A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06212999 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

617

Enrollment

INDUSTRY

Sponsor class

Conditions

Hidradenitis Suppurativa (HS)

Interventions

DRUG: Povorcitinib

Sponsor

Incyte Corporation